

## Listing of the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1-24. (CANCELED)
25. (CURRENTLY AMENDED) The method of claim ~~[[24]]~~28 wherein the compound is an inhibitor of *syk* kinase.
26. (CURRENTLY AMENDED) The method of claim ~~[[24]]~~28 wherein the compound is an inhibitor of calpain.
27. (CANCELLED)
28. (CURRENTLY AMENDED) A method of promoting fibrinolysis in a subject in need thereof having a preformed or terminally full thrombus comprising administering to the subject a compound selected from the group consisting of an inhibitor of *syk* kinase and an inhibitor of calpain, and a pharmaceutically acceptable carrier, and further comprising the step of administering to the subject an anti-platelet, anti-coagulation or anti-thrombotic agent.
29. (NEW) An *in vitro* assay to identify a compound to promote fibrinolysis in the presence of platelets, comprising identifying an agent which inhibits calpain activity, wherein the agent which inhibits calpain activity sustains eNOS activity.
30. (NEW) An *in vitro* method to identify a compound which promotes fibrinolysis in the presence of platelets comprising,
  - (a) screening a library of compounds in a calpain assay to identify an agent which inhibits calpain activity; and
  - (b) screening the agent identified in step (a) in a nitric oxide synthase assay to identify an agent which sustains eNOS activity,wherein an agent which inhibits calpain assay and sustains eNOS activity promotes fibrinolysis in the presence of platelets.
31. (NEW) The method of claim 30, wherein the eNOS activity is constitutive eNOS activity.

32. (NEW) The method of claim 28, wherein both an inhibitor or a syk kinase and an inhibitor of calpain is used